|
NCCN Guidelines® Insights - B-Cell Lymphomas, Version 3.2025 |
1.00 |
10/10/2025 - 12:00am to 10/10/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Breast Cancer, Version 5.2025 |
1.00 |
11/10/2025 - 12:00am to 11/10/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Merkel Cell Carcinoma, Version 1.2024 (JA copy) |
1.00 |
04/01/2026 - 12:00am to 12/31/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 7.2025 |
1.00 |
09/10/2025 - 12:00am to 09/10/2026 - 12:00am |
|
NCCN Guidelines® Insights - Soft Tissue Sarcoma, Version 1.2025 |
1.00 |
12/10/2025 - 12:00am to 12/10/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Survivorship, Version 2.2025 |
1.00 |
06/10/2025 - 12:00am to 06/10/2026 - 12:00am |
|
NCCN Guidelines® Insights - Thyroid Carcinoma, Version 1.2025 |
1.00 |
07/10/2025 - 12:00am to 07/10/2026 - 12:00am |
|
NCCN Guidelines® Insights - Uterine Neoplasms, Version 3.2025 |
1.00 |
08/10/2025 - 12:00am to 08/10/2026 - 12:00am |
|
NCCN Optimizing Patient Outcomes - From Mutation to Treatment: Understanding the Impact of New Targeted Therapies in Central Nervous System Cancers |
1.00 |
04/01/2026 - 12:00am to 09/11/2026 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - Hepatocellular Carcinoma: Latest Systemic Therapy Recommendations |
1.00 |
02/27/2026 - 12:00am to 08/16/2026 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - Hitting the Right Target: Updates in Biomarker-Directed Therapy for Non-Small Cell Lung Cancer |
1.00 |
04/09/2026 - 12:00am to 10/04/2026 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - In a Blink of an Eye: Updates in Frontline Therapy with Blinatumomab for Pediatric Acute Lymphoblastic Leukemia |
1.00 |
01/21/2026 - 9:43am to 07/11/2026 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - Recent Advancements in Chemoradiation Strategies for Locally Advanced Cervical Cancer |
1.00 |
04/13/2026 - 12:00am to 08/30/2026 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - When Prognosis Changes from Good to Poor: Treatment Options for Richter Transformation of Chronic Lymphocytic... |
1.00 |
01/22/2026 - 12:00am to 07/25/2026 - 11:59pm |
|
NCCN Tumor Boards: Managing Unique Toxicities and Immune-Related Adverse Effects of Treatment for Hodgkin Lymphoma |
1.00 |
01/20/2026 - 12:00am to 07/19/2026 - 12:00am |
Facebook
X
LinkedIn
Forward